[HTML][HTML] Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
MJ Armstrong, D Hull, K Guo, D Barton… - Journal of …, 2016 - Elsevier
Background & Aims Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic
steatohepatitis (NASH). Glucagon-like peptide-1 (GLP-1) analogues are licensed for type 2
diabetes, but no prospective experimental data exists in NASH. This study determined the
effect of a long-acting GLP-1 analogue, liraglutide, on organ-specific insulin sensitivity,
hepatic lipid handling and adipose dysfunction in biopsy-proven NASH. Methods Fourteen
patients were randomised to 1.8 mg liraglutide or placebo for 12-weeks of the mechanistic …
steatohepatitis (NASH). Glucagon-like peptide-1 (GLP-1) analogues are licensed for type 2
diabetes, but no prospective experimental data exists in NASH. This study determined the
effect of a long-acting GLP-1 analogue, liraglutide, on organ-specific insulin sensitivity,
hepatic lipid handling and adipose dysfunction in biopsy-proven NASH. Methods Fourteen
patients were randomised to 1.8 mg liraglutide or placebo for 12-weeks of the mechanistic …